Landmark Practice Advances
in STEMI and ACS

WebCAST CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

November 5, 2008

Expiration Date:

November 5, 2010

Intended Audience:

• Cardiologists, non-invasive specialists
• Prevention-oriented cardiologists
• Cardiologists, invasive specialists
• Coronary care unit (CCU) specialists and directors
• Specialists in invasive vascular management
• Program direc tors, cardiovascular medicine and emergency medicine
• Fellows in cardiovascular medi cine and emergency medicine
• Clinical pharmacists and pharmacologists
• Pharmacy directors (cardiovascular medicine)
• Investigators and clinical trial specialists, invasive cardiology

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Carlo Di Mario, MD, PhD, FESC, FACC, FRCP
Research Grants: Eli Lilly, Cordis Johnson and Johnson, Biotronik, Biosensors, Medtronic
Consulting or Speaker’s Fees: Boston Scientific, Abbott, The Medicines Company, Biosensors

Stefano Savonitto, MD, FESC
Speaker’s Honoraria: sanofi-aventis, Eli Lilly, The Medicines Company
Consultant Fees: Eli Lilly

Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FAHA
Consultant Fees: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, The Medicines Company, tns Healthcare, Vertex. Honoraria are donated to NPOs.
PI and/or on steering committees of several potentially related trials.
This presentation discusses off-label and/or investigational uses of antithrombotic drugs and interventional devices.

Michael M. Hirschl, MD
Speakers Honoraria: Takeda-Austria, Merck Sharp&Dome, Actelion and Servier Austria.
Research grant: Actelion-Austria

Program Faculty:

Program Co-Chairmen
Carlo Di Mario, MD, PhD, FESC, FACC, FRCP
Professor of Clinical Cardiology
Imperial College of Sciences, Medicine &
Technology
Consultant in Interventional Cardiology
Royal Brompton Hospital
London, UK

Stefano Savonitto, MD, FESC
Prima Divisione di Cardiologia
Dipartimento Cardiologico “Angelo De Gasperis”
Ospedale Niguarda Ca’ Granda
Milano, Italy

Distinguished Presenters
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FAHA
Chief of Cardiology
VA Boston Healthcare System
Director of the Integrated Cardiovascular
Intervention Program
Brigham and Women’s Hospital and the
VA Boston Healthcare System
Harvard Medical School
Boston, Massachusetts

Michael M. Hirschl, MD
Associate Professor
Head of the Emergency Room
Medical Department of Cardiology and Intensive
Care Medicine
Landesklinikum St. Pölten
A-3100 St. Pölten, Austria

Educational Objectives:

Participants in this CME-certified WebCAST will:

• learn how recently issued ESC and AHA/ACC guidelines for UA/Non ST-elevation myocardial infarction and STEMI are best applied to appropriately risk-stratified patients with UA/NSTEMI and STEMI.
• learn to understand the implications of recent clinical data, trials, and recommendations on upstream management of STEMI and NSTEMI.
• learn to apply guidelines and expert, consensus-based recom mendations in order to optimize invasive vascular management of patients with high risk ACS
  
  

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved